GNOM - ETF AI Analysis
Top Page
Global X Genomics & Biotechnology ETF (GNOM)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and in recent months, indicating positive momentum in its focused area of the market.
Leading Genomics and Biotech Holdings
Many of the top holdings, including well-known genomics and biotechnology companies, have delivered strong year-to-date performance, helping drive the fund’s returns.
Targeted Exposure to a Growth Theme
The fund concentrates on genomics and biotechnology, giving investors focused access to a long-term growth theme in health care innovation.
Negative Factors
High Sector Concentration
With almost all assets in health care and related fields, the ETF is heavily exposed to swings in one sector rather than being broadly diversified.
Limited Geographic Diversification
The fund is overwhelmingly invested in U.S. companies, offering very little exposure to international markets.
Moderate Expense Ratio
The ETF’s fees are not extremely high but are meaningfully above what broad market index funds typically charge, which can slightly reduce long-term returns.
GNOM vs. SPDR S&P 500 ETF (SPY)
AUM79.65M
RegionGlobal
Expense Ratio0.50%
Beta1.17
IssuerGlobal X
Inception DateApr 05, 2019
Dividend Yield1.2%
Asset ClassEquity
Index TrackedSolactive Genomics Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume15,605
30 Day Avg. Volume24,586
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
71.15Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering50
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GNOM Summary
The Global X Genomics & Biotechnology ETF (GNOM) is a fund that follows the Solactive Genomics Index, focusing on companies working in gene editing, DNA sequencing, and personalized medicine. It mainly holds U.S. health care and biotech firms, including well-known names like Illumina and Moderna. Someone might invest in GNOM to tap into the long-term growth potential of cutting-edge medical and genetic technologies while spreading their money across many companies in this niche. However, this ETF is heavily focused on biotech, so its price can be very volatile and may rise or fall sharply with news and market sentiment.
How much will it cost me?The Global X Genomics & Biotechnology ETF (GNOM) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average because it is actively managed to focus on a specialized sector like genomics and biotechnology, which requires more research and expertise. It’s designed to give investors exposure to cutting-edge companies in this innovative field.
What would affect this ETF?The GNOM ETF, focused on genomics and biotechnology, could benefit from advancements in gene editing and personalized medicine, as well as increased global healthcare spending and innovation. However, it may face challenges from regulatory hurdles, high research costs, and potential market volatility in the healthcare sector. Its global exposure and top holdings in cutting-edge companies position it well for growth but also make it sensitive to changes in economic conditions and industry-specific risks.
GNOM Top 10 Holdings
GNOM is a pure play on cutting-edge genomics, with nearly all its firepower in health care names and a global tilt. 10x Genomics and Twist Bioscience have been the fund’s high-octane engines lately, rising on strong momentum despite ongoing profitability issues. Illumina and Guardant Health are also helping, though Guardant’s recent wobble shows the ride can be bumpy. Natera and Veracyte add steady, if sometimes mixed, support. Overall, GNOM is a concentrated bet on genomic innovation, where future promise often runs ahead of current earnings.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Guardant Health | 6.37% | $5.08M | $21.74B | 259.42% | 61 Neutral | |
| Illumina | 5.54% | $4.41M | $31.03B | 101.30% | 71 Outperform | |
| Twist Bioscience | 4.95% | $3.95M | $5.70B | 234.52% | 43 Neutral | |
| 10x Genomics | 4.92% | $3.92M | $6.00B | 243.64% | 60 Neutral | |
| Natera | 4.54% | $3.62M | $38.35B | 97.96% | 73 Outperform | |
| Bio-Techne | 4.34% | $3.46M | $11.29B | 31.45% | 64 Neutral | |
| Arrowhead Pharmaceuticals | 4.04% | $3.22M | $11.92B | 422.38% | 57 Neutral | |
| BioMarin Pharmaceutical | 3.91% | $3.11M | $11.60B | -0.52% | 75 Outperform | |
| Vertex Pharmaceuticals | 3.84% | $3.06M | $121.09B | -0.33% | 78 Outperform | |
| Qiagen | 3.65% | $2.91M | $8.53B | -19.97% | 77 Outperform |
GNOM Technical Analysis
Positive
―
Price Trends
53.01
Positive
48.92
Positive
47.31
Positive
Market Momentum
0.31
Positive
56.68
Neutral
74.27
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNOM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 55.18, equal to the 50-day MA of 53.01, and equal to the 200-day MA of 47.31, indicating a bullish trend. The MACD of 0.31 indicates Positive momentum. The RSI at 56.68 is Neutral, neither overbought nor oversold. The STOCH value of 74.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNOM.
GNOM Peer Comparison
Comparison Results
Performance Comparison
GNOM
Global X Genomics & Biotechnology ETF
55.81
21.29
61.67%
EVX
VanEck Environmental Services ETF
―
―
―
FDCF
Fidelity Disruptive Communications ETF
―
―
―
CSNR
Cohen & Steers Natural Resources Active ETF
―
―
―
HELX
Franklin Genomic Advancements ETF
―
―
―
GNMX
Corgi Genomics & Precision Medicine ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents